

ABcann  
GLOBAL

*changing lives globally*



# Notice Regarding Forward-Looking Statements



Certain information included in this document contains forward-looking statements. These forward-looking statements include, among others, statements with respect to the Company's objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to the Company's beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond the Company's control, could cause actual results may differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, risks relating to industry, competition, customer, legal, taxation and accounting matters. The foregoing list of factors that may affect future results is not exhaustive. When reviewing the Company's forward-looking statements, readers should carefully consider the foregoing factors and other uncertainties and potential events.



A Globally Licensed, Cost Efficient Producer of Premium  
Quality Organic Standardized Medicinal Cannabis



# Well-Positioned

To capitalize in the fast-changing medicinal cannabis market

Infrastructure in place to take advantage of a **\$4.9 to \$8.7 BILLION** marketplace



**Health Canada approved  
ACMPR Licensed Provider**



**Production capacity:**  
1,000KG



**Phase 1:**  
Fully operational  
14,500 sq. ft. facility



**Phase 2:**  
150,000 sq. ft. facility with a  
production target capacity of  
40,000 kg/annum (Licence pre  
approval for 71,000 sq. ft. 20,000  
kg / annum)



**State of the art Facilities**  
Computer controlled growing  
system, for consistent  
pharmaceutical-grade product  
with high yields



**Sales & Marketing Strategy**  
Established patient-client  
care systems



**Global Outlook**  
Active global initiatives  
Europe | Israel | Australia


Total 65 Acres, serviced industrial  
zoned land, which can  
accommodate up to 1.2 million sq.  
ft. production facility

# Potential of \$8 BILLION in Sales by 2024 in the Canadian Market

According to Cannacord, recreational marijuana adds to the bottom line

“The rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term until production capacities catch up by 2020, according to Canaccord.

— Canaccord Genuity Group Inc., November 2016



# Market Comparable to Tobacco and Alcohol Sales



Deloitte estimates liquor sales between **\$5 billion** and **\$8.7 billion** annually




Canaccord estimates the number of marijuana users rising steadily in the first years of legal marijuana, to nearly **4 million**

That would make the legal marijuana market similar in size to hard liquor sales or wine sales.

CANACCORE Genuity

Number of registered patients and kgs sold per Health Canada



Source: Stats Can, Canopy Growth Corp, Dundee Capital Markets Estimates

# ABcann Advantage

YTD Customer Growth Rate:  
**30%** month over month

Customer Retention Rate: **94.7%**

Current Yield Rate:  
**100%** over industry average

R&D results, significant yield  
increase over industry average

High yield results in low cost per  
gram



## Driving Future Success...

**Organically Grown,  
No Pesticides**

**Sustainable profitability**

**Customer growth  
and Retention**

# ABcann Advantage: Research Partnerships

With the University of Guelph's Controlled  
Environmental System Research Facility



“The challenge is to reliably homogenize the environmental experience for the plants so they all behave the same and produce the same medicinal compounds. The only way to achieve that is to grow plants in a very precisely controlled, predictable and reproducible manner.”

**Dr. Michael Dixon**  
University of Guelph



## Controlled environmental system research

\$1.5M - 3 year Partnership carried out in ABcann's Vanluven facility in Napanee

Dry Flowers Mass Per Plant (g)

Plant	Control Treatment	Yellow Treatment	Orange Treatment
1	70.0	86.1	70.4
2	108.7	77.7	97.9
3	105.1	82.3	96.2
4	110.7	97.3	83.6
5	120.0	108.6	84.1
6	137.2	103.0	114.9
7	105.3	108.7	101.3
Average	108.1	94.8	92.6



Source: University of Guelph



## ABcann Advantage: Pharmaceutical Grade Plant Standardization

“After visiting ABcann’s production facility in Canada, I personally witnessed that their production technologies put them in a class with the best in the world in their ability to produce standardized pharmaceutical grade cannabis.”

Perry Davidson  
Founder, Syqe Medical



ABcann has successfully shipped product to Syqe in Israel and are involved in ongoing testing and R&D.

## “Teva to market Syqe Medical cannabis inhaler for pain management in Israel”

First World Pharma

The World's First  
Selective-Dose Pharmaceutical Grade  
Medicinal Plant Inhaler



# ABcann Advantage: Advanced Technology



## Why we have developed an exclusive, computer-controlled environmental system



Our system can replicate the natural environment of any geographical location for a product that is both superior in quality and repeatable from batch to batch.



We have custom, scalable growing chambers with proprietary LED lighting, which we can replicate anywhere in the world.



Organic fertilizers and soil media, with no pesticides, permit us to deliver products which are natural and safe.



A clean, strictly controlled indoor environment eliminates the need for pesticide applications. The final product is free of chemical toxins, to ensure maximum therapeutic benefit.

ABcann's advanced growing technology not only creates a consistent, organically grown, pesticide free standardized product—but the computer-controlled environment brings costs DOWN



# ABcann Advantage: Our Approach

Scalable Production | Computer-Controlled  
Environment | Standardized product

Organically Grown  
Pesticide Free



Every variable in the growing, curing and harvesting process is monitored and controlled for a high-quality, standardized cannabis product

Air quality

CO<sub>2</sub> levels

Oxygen levels

Water quality and volume

Light spectrum and cycles

Temp. and Humidity


Plant nutrition

Climate controlled curing process

This advanced approach also results in...

# ABcann Advantage: Above Industry Yields

## Efficient Yields / Sq. Ft.



### Assumptions & Sources:

- Yield per sq. ft. is calculated based on total flowering room area
- PI Financial estimates and company financials



# ABcann Advantage: Unique Cost Savings

Computer-controlled growing environment  
results in lower costs per gram

Precision control in the growing  
process nets maximum cost savings



Yields significantly  
greater than traditional  
growing processes



Less water and  
energy usage




Optimized use of  
fertilizer and nutrition



No mould or bacteria  
for greater harvests

A higher-quality product costing less  
per gram to produce



# ABcann Advantage: Premium Medical Products

Hand trimmed | Patient Ready | Affordable

ABcann produces a variety of strains and compound combinations for the best therapeutic results from high THC, to balanced, to high CBD

A variety of THC and CBD levels give healthcare providers the best options for recommending the appropriate prescription to treat ailments, such as...

- Arthritis
- Diabetes
- Alcoholism
- MS
- Chronic pain
- Schizophrenia
- PTSD
- Depression
- Antibiotic-resistant infection
- Epilepsy
- And more

ABcann  
GLOBAL

<b>SI:Med</b> THC: 22.8% CBD: <0.07% Hand Trimmed \$14/gram	<b>SI:Med</b> THC: 21.0% CBD: <0.07% Patient Ready \$8/gram	<b>NC:Med</b> THC: 5.66% CBD: 10.3% Hand Trimmed \$14/gram
<b>NC:Med</b> THC: 5.73% CBD: 10.3% Patient Ready \$8/gram	<b>WP:Med</b> THC: 22.2% CBD: <0.07% Hand Trimmed \$12/gram	<b>WP:Med</b> THC: 20.4% CBD: <0.07% Patient Ready \$7/gram
<b>IC:Med</b> THC: 20% CBD: <0.07% Hand Trimmed \$10/gram	<b>IC:Med</b> THC: 21.0% CBD: <0.07% Patient Ready TBA	<b>OP:Med</b> THC: 20.8% CBD: <0.07% Hand Trimmed \$10/gram
<b>OP:Med</b> THC: 16.6% CBD: <0.07% Patient Ready \$6/gram	<b>SN:Med</b> THC: 17.0% CBD: <0.07% Hand Trimmed \$8/gram	<b>DC:Med</b> THC: 5.89% CBD: 10.5% Affordable \$5/gram

"I have switched from both Tilray and Tweed/Bedrocan to ABcann in April and have not looked back. They grow a properly grown product... that is enjoyable each and every time."  
[Heathrow](#) - Oct 2016



# ABcann Advantage: Licensed Facilities for Production


Capabilities now and into the future



Phase 1: Vanluven Facility	Phase 2: Kimmitt Facility	Future Expansion
<ul style="list-style-type: none"><li>• 14,500 sq. ft. facility in Napanee, Ontario</li><li>• Production Capacity: 1000 kg Annually</li><li>• Completely licensed and fully operational</li><li>• Additional bloom chamber to be added in H1 2017</li></ul>	<ul style="list-style-type: none"><li>• Land owned for future build-out</li><li>• 71,000 sq. ft. facility planned for Napanee, Ontario</li><li>• Construction to begin Imminently</li><li>• Production Capacity: 20,000 kg Annually</li></ul>	<ul style="list-style-type: none"><li>• 65 acres ready for development</li><li>• 100% ownership</li><li>• Estimated 1.2M sq.ft.</li><li>• Power/water/waste infrastructure in place</li></ul>

## Capabilities now and into the future

14,500 sq. ft.  
Vanluven Facility




100% owned 65 Acre  
ABcann Parcel





# Capacity Potential Abcann Facilities




## Assumptions

- The Vanluven forecast is based on current production abilities and current buildout optimization.
- The Kimmitt forecast is based on the buildout plan for 4 PODS (a POD is 4 bloom rooms plus support chambers). The projections call for the 4 PODS to be phased in through 2018 and all 16 bloom rooms to be online by October 2018.
- Yield is set at 2 lbs per light which provides approx. 60,000 grams per crop, 6 times per year in 2018. The yield increases each year based on research being undertaken with the University of Guelph. The yield is split 2/3 to bud and 1/3 to trim.

# FY2017 Objectives

## Optimizing for operational growth and scaling





# CAP Table

As at Jan. 30<sup>th</sup>/2017

<b>Shell (Panda) + ABcann Shareholders:</b>	<b>79,324,261</b>
<b>Current Debentures:</b> Conversion rights on a 20% discount on the public price	<b>\$5,000,000</b>
<b>Current Outstanding:</b>	<b>79,324,261</b>
<b>Warrants:</b> Complete exercise of warrants brings in approximately \$20.5 million	<b>37,404, 430</b>
<b>Options:</b>	<b>6,131,951</b>
<b>Total Issued and Outstanding:</b>	<b>122,860,647</b>
<b>Concurrent Financing to be Completed with RTO:</b>	<b>\$8,000,000 @ price TBD</b>

# Comparable ACMPR Companies

## Valuation based on Funded Capacity

Company	Symbol	Market Cap	Licensed Sq.ft. - 2017
Aurora	ACB	\$763M	55,000
Organigram	OGI	\$262M	41,000
Supreme	SL	\$275M	16,500
Emblem	EMC	\$260M	14,500
Emerald	EMH	\$103M	14,000
ABcann	N/A	N/A	Current - 14,500 sq. ft. Vanluven Facility Future - 71,000 sq. ft. Kimmett Facility Potential for 1.2 million sq. ft. Facility



# Highly Experienced Management Team



## **Ken Clement - Founder, Executive Chairman**

Ken has been the key component and driving force behind ABcann's development. His vision is unique in the medical cannabis sector with the concept of standardized production and dosage. Ken enjoys a strong rapport with Health Canada and numerous strategic partnerships worldwide. "I have only met briefly with Ken but anyone who is able to take an idea and with Pitbull determination transform it into a world class corporation like ABcann, in such a short time, is truly a miracle worker." Dr. Mike Shannon, former Deputy Surgeon General Canada.



## **Aaron Keay - CEO**

Aaron has spent the last 11 years working in the capital markets across a broad spectrum of sectors. Aaron's roles have ranged from corporate finance, senior management and board member. He has overseen finance and M&A transactions and Capital raising, helping private companies navigate from the private to public markets. His work and leadership has helped raise ~\$250m for public and private market issuers.



## **Jenny Guan - CFO**

Jenny has been with ABcann since 2012 and is responsible for corporate financial reporting, operations, treasury, tax, budget planning, corporate policies, internal controls and ABcann's relationship with external auditors. Coming from a business accounting background, she has over 15 years experience in various key leadership roles in business operations, finance, and program management.



## **Andrew LaCroix - VP, Business Development**

Andrew LaCroix started his legal career working for blue chip firms in Vancouver, and has run his own practice on Vancouver Island since 2008. Andrew has been involved with ABcann since its inception as general counsel, drafting and submitting ABcann's initial Health Canada license application and acting as general counsel on a host of different business and legal issues. Andrew will provide ABcann Global Corporation with ongoing advice, and play a large role in both domestic and international business development.



## **Neil Kapp - President, Operations**

Neil has over 30 years of experience in operating and managing businesses, in both the commercial development and recreational facilities market place, with annual revenues in excess of \$6.5M. Neil serves as managing partner and CFO for this group of companies, which has over 200 employees.



## **John Molloy - Executive Consultant**

Former President and CEO of PARTEQ Innovations at Queen's University for 28 years. His leadership led to the formation of 48 companies based on Queen's research, with more than \$1.7 billion invested to date in those companies.

# Board of Directors



**Ken Clement**

Founder, Executive Chairman



**Aaron Keay**

CEO, Director



**Andrew Lacroix**

VP Business Development, Director



**Daryl Kramp**

Was the Member of Parliament for the riding of Prince Edward-Hastings from 2004 through October of 2015. His past political experience includes six years as a municipal councilor and deputy reeve in the municipality of Madoc. Mr. Kramp brought vast experience in the private sector to his role. He has created and operated several successful business ventures in the fields of retail, wholesale and hospitality.



**John Easson**

John has over 23 years of experience advising companies on Corporate Finance, and Mergers and Acquisition transactions. Whether it be through his own BE Capital Advisors practice or his 15 years working for BMO, RBC and Scotiabank, John has significant transaction experience with a range of companies from small private start-ups to some of Canada's largest public companies.



**Paul Lucas**

Mr. Lucas served as President and CEO of GlaxoSmithKline Canada from 1994 until he retired in 2012. Currently Mr. Lucas is a member of the Board of Directors of RnA Diagnostics Inc and He is also Chair of the Board of EcoSynthetix Inc., Induran Ventures Inc., and Life Sciences Ontario. He received his BSc (Honours) in Biology and Chemistry from Queen's University, and obtained his Chartered Directors designation (CDir) from the Directors College.



# Advisory Board

Led by the “Father of Cannabis Medicine”



**Raphael Mechoulam, PhD**

- Organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem
- In 1963 isolated cannabidiol (CBD)
- First scientist to isolate tetrahydrocannabinol (THC)
- Over 25 academic awards including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012



**Mike Dixon, PhD**

- Professor, School of Environmental Sciences, Director of the Controlled Environment Systems Research Facility, University of Guelph
- Formed the Space and Advanced Life Support Agriculture (SALSA) program
- Leads the world in technology developments and research dedicated to studying plant and microbial interactions in advanced life support systems



**Michael E. Shannon, M.A., M.Sc., M.D.**

- Served in the Canadian Forces for 31 years, retiring at the rank of Commodore as Deputy Surgeon General for Canada
- Directed a phase III clinical trial in Canada, the U.S. and Great Britain for an artificial blood substitute product
- Senior Medical Advisor for the Canadian Public Health Agency on special assignment directing the rebuilding of the Emergency Medical Response Capacity for Canada, the largest emergency response exercise in the history of the country
- Directly responsible for the first approved human clinical trial in North America examining the efficacy of O3 delivered via autohemotherapy in the treatment of AIDS.
- Has served as the Senior Media Advisor to Medizone International since 2002, and appointed the President of the Canadian Foundation for Global Health in 2008



**Donald I. Abrams, MD**

- Chief of the Haematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California
- Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine
- Co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology



**Chris Hudalla, PhD**

- Founder and Chief Scientific Officer of ProVerde Laboratories, Inc.
- More than 25 years of research experience in analytical chemistry, spectroscopy and chromatographic method development
- Recognized worldwide as an expert in the field of traditional Reverse Phase Liquid, Supercritical Fluid and Convergence Chromatography



**Paul Daeninck, MD**

- Medical Oncologist and palliative medicine consultant with Cancer Care Manitoba and the Winnipeg Regional Health Authority (WRHA) Palliative Care Program. He is an Assistant Professor and Leader for the Palliative Care Longitudinal Theme for Undergraduate Education at the College of Medicine, University of Manitoba.
- Dr. Daeninck is the author of several research papers as well as textbook chapters. He serves as a reviewer for palliative medicine journals. He has been active in medical student and resident education, and has ongoing research interests in several aspects of palliative medicine, including that of cannabinoid use in patients with cancer.

# High-Growth Potential

Management, operations and sales in excellent position



Over 65 acres for growth — one of the largest in industry



Fully capitalized to complete phase 2 construction



Low costs underpin attractive cash-flow potential



Sales growth with revenue capacity and improving cash-flow



Cost and margin profile improving



Established operations team and Board of Directors



# ABcann Global Inc.

## ABcann Advantage:

- Global Reach
- Technology Partnerships
- Corporate Partnerships
- Exclusive Technologies
- High Yields, Lower Cost
- Premium Organic Producer
- Expandable Modular Design
- Experienced Management Team
- Strong Board of Directors
- Internationally Respected Advisory Board
- Employee Pride of Ownership

ABcann  
GLOBAL

**Canadian Market estimated to be between \$3 and \$8 billion.**

**ABcann is well positioned to compete in the Canadian Market.**

**ABcann has begun its Global Expansion to participate in the European, Australian and Israeli markets.**





Contact ABcann Medicinals  
for more information...

### ABcann Investor Relations

Aaron Keay  
604-323-6911  
[aaron@abcannglobal.com](mailto:aaron@abcannglobal.com)

### Corporate Headquarters

126 Vanluven Road  
Napanea, ON K7R 3L2  
Canada